We suggest that during TGF-β1 treatment either the protein level, sensitivity or signaling of PPAR-β/δ dominates in IPF and that of PPAR-γ in control fibroblasts with regard to catalase protein content and its activity. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.